Tenofovir disoproxil fumarate with emtricitabine and efavirenz; tenofovir disoproxil fumarate with emtricitabine and rilpivirine; tenofovir disoproxil fumarate with emtricitabine, elvitegravir and cobicistat
Brand: Atripla, Eviplera, Stribild
PBAC's latest decision on Tenofovir disoproxil fumarate with emtricitabine and efavirenz; tenofovir disoproxil fumarate with emtricitabine and rilpivirine; tenofovir disoproxil fumarate with emtricitabine, elvitegravir and cobicistat: Deferred (2019). Considered for Treatment of HIV-1 infection in adults. These are fixed-dose combination products containing tenofovir with emtricitabine and various third agents (efavirenz, rilpivirine, or elvitegravir/cobicistat).
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Adults with HIV-1 infection currently treated with Atripla, Eviplera, or Stribild who have demonstrated reluctance to switch to alternative therapies, particularly newer PBS-listed therapies containing tenofovir alafenamide.
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
Not applicable — this is a delisting review, not a health economic evaluation of a new indication or formulation. No ICER was calculated.